Daily Stock Analysis, CORT, Corcept Therapeutics Inc, priceseries

Corcept Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
15.81
Close
16.09
High
16.26
Low
15.54
Previous Close
15.77
Daily Price Gain
0.32
YTD High
25.96
YTD High Date
Jan 29, 2018
YTD Low
13.39
YTD Low Date
Feb 9, 2018
YTD Price Change
-2.05
YTD Gain
-11.30%
52 Week High
25.96
52 Week High Date
Jan 29, 2018
52 Week Low
8.37
52 Week Low Date
Feb 23, 2017
52 Week Price Change
7.44
52 Week Gain
86.01%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 22. 2017
8.51
Mar 14. 2017
9.69
14 Trading Days
13.83%
Link
LONG
Mar 24. 2017
10.12
Apr 5. 2017
10.79
8 Trading Days
6.63%
Link
LONG
May 11. 2017
10.04
May 30. 2017
11.57
12 Trading Days
15.27%
Link
LONG
Aug 28. 2017
14.69
Sep 21. 2017
17.41
17 Trading Days
18.51%
Link
LONG
Sep 22. 2017
18.20
Oct 10. 2017
19.32
12 Trading Days
6.13%
Link
LONG
Jan 9. 2018
19.94
Jan 30. 2018
23.26
14 Trading Days
16.64%
Link
Company Information
Stock Symbol
CORT
Exchange
NasdaqCM
Company URL
http://www.corcept.com
Company Phone
650.688.8803
CEO
Joseph K. Belanoff
Headquarters
California
Business Address
149 COMMONWEALTH DRIVE, MENLO PARK, CA 94025
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001088856
About

Corcept Therapeutics, Inc. engages in the development of drugs for the treatment of severe psychiatric, neurological, and metabolic disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff On May 13, 1998 by and is headquartered in Menlo Park, CA.

Description

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer. In addition, it develops CORT125134 for the treatment of patients with Cushing's syndrome and solid-tumor cancers; and CLIA-validated assay to measure expression of the gene FKBP5, which is stimulated by cortisol activity at glucocorticoid receptor. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.